What topical finasteride is
Topical finasteride applies the same active ingredient as the 1mg oral tablet directly to the scalp, on the theory that local application might achieve similar hormonal effects on hair follicles while reducing how much of the drug enters the bloodstream. The idea is appealing: potentially similar benefit to oral finasteride, with fewer systemic (body-wide) side effects.
Regulatory status: there is no licensed topical finasteride product in the UK. Where it’s prescribed, it’s supplied as an unlicensed compounded “special,” made up by a pharmacy to a prescriber’s specification rather than manufactured and licensed as a standard product. This is different from oral finasteride (Propecia and generics), which is a licensed UK medicine with a full product licence and standard manufacturing.
What the evidence actually shows
This is the honest, and less exciting, part: topical finasteride’s evidence base is considerably smaller than oral finasteride’s. The largest recent real-world dataset comes from a US telehealth provider, tracking 638,629 patients prescribed compounded topical finasteride between 2021 and 2025. Only 23.7% of patients completed a follow-up survey, and of those, 80.4% reported satisfaction and only 2.7% reported side effects; just 0.04% proactively contacted their care team about an adverse effect.
Two things are worth knowing before treating that low side-effect figure as reassuring. First, this is a US population using a private telehealth platform, not a UK clinical trial, and it’s retrospective with no control group, so it can’t prove topical finasteride caused the good outcomes reported. Second, the 23.7% follow-up rate is low and likely biased toward people who were doing well enough to bother responding; people who had a bad experience and simply stopped using the product and never engaged again wouldn’t show up in that 2.7%. A genuinely low side-effect rate would be good news, but this dataset can’t fully prove it’s genuinely low, rather than under-reported.
Separately, some pharmacovigilance (drug-safety monitoring) data comparing topical and oral finasteride has suggested fewer sexual and psychiatric side-effect signals with topical use, which is plausible given lower systemic absorption, but this is signal-level surveillance data, not proof from a controlled trial.
What this means practically
Topical finasteride is not “proven safer” than oral finasteride; it’s plausible that it carries a lower systemic risk, based on how it’s absorbed, but the evidence to confirm that at a UK-regulator level of confidence doesn’t yet exist. It also is not backed by the same scale of randomised controlled trial evidence as the oral tablet. Because it’s an unlicensed “special,” you should expect a UK prescriber to explain this status clearly, not present it as an equivalent, standard, licensed alternative.
How UK clinics handle it
As an unlicensed product, topical finasteride is only available through a private prescriber willing to specify a compounded formulation, made up by a pharmacy able to dispense specials. It isn’t stocked as a standard over-the-counter or repeat-prescription item the way oral finasteride or topical minoxidil are.
Alternatives
See our finasteride vs minoxidil comparison for how the licensed oral tablet compares with topical minoxidil, or compare UK hair loss clinics to see which services offer which formulations.